XML 29 R19.htm IDEA: XBRL DOCUMENT v3.25.3
Note 8 - Segment Reporting (Tables)
9 Months Ended
Sep. 30, 2025
Notes Tables  
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]
  

Three Months Ended

  

Nine Months Ended

 
  

September 30,

  

September 30,

 
  

2025

  

2024

  

2025

  

2024

 

Revenues

 $  $  $  $ 

Less:

                

Clinical and regulatory

  1,680,061   1,740,207   5,046,279   5,845,783 

Manufacturing

  188,532   589,548   1,144,195   1,109,388 

Research

  313,323   240,701   950,640   236,855 

General and administrative support

  1,144,444   1,331,484   4,192,630   6,605,217 

Non-cash expenses(1)

  19,553   421,498   663,243   3,041,195 

Other income

  2,405   8,080   14,056   58,851 

Plus:

                

Other financing costs

  (455,549)     (455,549)   

Realized and unrealized loss

  (183)  (629)  (262)  (1,115)

Segment and net loss

 $3,799,240  $4,315,987  $12,438,742  $16,780,702